: iStockAnalyst.com Symbols Feed

Trading FDA Decisions: 14 Extreme Trades

Wed, 11 Mar 2009 16:25:00 GMT

Below is a summary of companies from the BioMedReports.com FDA Decision Date Calendar which have market caps below $200M, making them ideal candidates for extreme stock price volatility trades as their decision dates become imminent. Dyax Corp. (DYAX) secured a narrow approval from a FDA Advisory Panel in early February (with a 6-5-2 vote) for its Kalbitor (ecallantide or DX-88) BLA with a PDUFA date of 3/23/09, which is designated for priority review in the treatment of acute attacks of hereditary angioedema (HAE is a rare disorder marked by severe swelling which can be fatal if the throat area is involved). The panel debated the need for an effective treatment for this rare, potentially dangerous condition against the 3% higher incidence of allergic reactions (13% versus 10%) in patients taking[More...]

Stem Cell Index Soars on Lift of Funding Ban

Tue, 10 Mar 2009 01:50:00 GMT

The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 14.2% at a value of 3,387[More...]

Global Stem Cell and Regenerative Medicine Index

Wed, 18 Feb 2009 00:55:00 GMT

The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close[More...]

Nine Stocks, Mostly Earnings Movers

Mon, 11 Aug 2008 14:31:00 GMT

NOBL is one I’ve been trading and writing about—check out all the testimonials from TIMalert subscribers HERE…$4.80-$4.90 is support, if it cracks that, it could tank 50 cents or so, so far it’s been holding on…I doubt I’ll short this as it is an earnings play so no matter what happens, it really shouldn’t collapse quickly like pump and dumps doEVSO is a spmmaer goin higher, wasting an awful lo of volume though and still hasn’t broken out…hopefully these spammers are the real deal and can push this thing waaay up, I’ll probly wait til a confirmed breakout above $3 to buyPRS is a financial play going up gradually, two strikes against it, I’m not interested in shortingVUOC has been spiking from 50 cents/share to $1—they’ve supposedly developed energy[More...]

Take a Look at These Thirteen Stocks

Thu, 07 Aug 2008 15:28:00 GMT

I know, I know you want some stock trades, well, it’s been boring, welcome to PennyStocking, there’s not gonna be a trade every day or even every week, especially during this, the slowest month of the year. Deal with it and don’t force trades…and most of all, stop emailing me about when … (visit site to read more)[More...]

Post Fed Earnings

Wed, 06 Aug 2008 14:33:00 GMT

Good morning. Investors are sorting through a number of earnings reports including from Cisco Systems (CSCO), Freddie Mac (FRE), Sprint (S), Time Warner (TWX), Priceline.com (PCLN), Ambac (ABK), & Whole Foods (WFMI). Also, oil is trading slightly higher ahead of the government's weekly energy inventory report at 10:35AM. In the early going, premarket futures are mixed as the market hopes to[More...]

Ten Stocks To Consider Short Selling

Thu, 03 Jul 2008 15:43:00 GMT

HYGSAlerted TIMalert subscribers that I shorted this at $2.29 in the morning, hoping for a gradual fade into negativity saying “i think if it takes out 2.28-2.25ish, it can go under $2”, DEAD ON, stock dropped to under $2 too quick for my comfort, I bailed for quick $250ish profit (detailed post coming)….woulda shorted into the afternoon fade (yes, that’s a perfect one), but I had no trades left, definitely reserve shares to short, pray it spikes again as this could really fall to sub-$1.80 if the setup is right, just gotta wait and see the price actionTGCAlso alrted TIMalert peeps to my horrific amateur mistake on this, shorted accidentally at $3.49, brings up [More...]

Sara Lee CEO Barnes Announces Plans for Upcoming Acquisitions

Wed, 20 Feb 2008 17:58:34 GMT

(NewsVisual, powered by IntellectSpace )-- Sara Lee Corp (NYSE: SLE) could be seeing some major growth in 2008 as CEO Brenda Barnes announced that the food company is ready for takeovers. Barnes became Sara Lee’s CEO in 2005 and has since helped the company shed some of its businesses to tighten operations. Yesterday at a food-industry confer[More...]

Isolagen, Inc. Receives Notification Letter from Amex

Fri, 20 Mar 2009 20:55:00 GMT

Isolagen, Inc. today announced that on March 17, 2009, it received notice from the Amex notifying the Company it is not in compliance with Section 1003 of the Exchange's Company Guide . Specifically, the Exchange staff noted that the Company sustained losses which are so substantial in relation to its overall operations or its existing financial sources that is appears questionable, in the opinion of the Exchange, as to whether the Company will be able to continue operations and/or meet its obligations as they mature. As previously disclosed, the Company received a notice from the Exchange on March 12, 2008, advising the Company that it was not in compliance with Sections 1003 - of the Company Guide. The Company's plan to bring itself back into compliance by September 14, 2009 in connection with the previous notice was accepted by the Exchange in August 2008.[More...]

Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration

Mon, 09 Mar 2009 12:57:00 GMT

Isolagen, Inc. today announced that the Company has submitted a Biologics License Application for Isolagen Therapy, a novel, first-in-class cellular therapy for the treatment of wrinkles/nasolabial folds, to the U.S. Food and Drug Administration . The Company's wrinkles/nasolabial folds Phase III trials were conducted under an FDA Special Protocol Assessment.[More...]

Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant

Thu, 05 Mar 2009 13:20:00 GMT

-Company Provides Update on Cash Position-[More...]

Isolagen, Inc. Provides Analysis of Data from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles

Thu, 23 Oct 2008 01:54:00 GMT

Isolagen, Inc. presented today an analysis of results from the completed pivotal Phase III studies of the Isolagen Therapy for the treatment of nasolabial folds, or wrinkles. Both studies, conducted under a U.S. Food and Drug Administration Special Protocol Assessment , reported statistically significant results meeting all primary endpoints. The analysis was presented today in a company webcast. Please visit www.isolagen.com for the complete audio and slide presentation.[More...]

Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study

Tue, 21 Oct 2008 12:27:00 GMT

Isolagen, Inc. announced today that all injections have been completed in the Phase II/III Study IT-A-008 investigating Isolagen Therapy for the treatment of moderate to severe facial acne scars. Further, approximately half of all of the study participants have completed the final observation visit. Isolagen anticipates the acne study will conclude in the first quarter of 2009.[More...]

Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies

Mon, 20 Oct 2008 12:26:00 GMT

Isolagen, Inc. announced today that the Company will host an investor conference call and webcast on Wednesday, October 22 at 4:30 PM Eastern Time to present an analysis of the data from the Isolagen Therapy Phase III pivotal studies for the treatment of nasolabial folds, or wrinkles. On August 5, 2008, Isolagen reported positive top-line efficacy and safety results from these two studies, which met all primary endpoints and were highly statistically significant.[More...]

Isolagen to Present at the JMP Securities Healthcare Focus Conference

Fri, 03 Oct 2008 12:56:00 GMT

Isolagen, Inc. announced today that Declan Daly, Chief Executive Officer, will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 3:30 p.m. at Le Parker Meridien hotel in New York, New York.[More...]

Isolagen, Inc. Reaches Agreement in Principle to Settle Its Class Action and Derivative Action Lawsuits

Thu, 25 Sep 2008 12:57:00 GMT

Isolagen, Inc. announced today that it has reached an agreement in principle to settle its securities class action lawsuit and its two derivative actions against the Company and certain of its current and former officers and directors .[More...]

Isolagen Reports Positive Results from Open Label, Phase II Study of Isolagen Therapy(TM) of the Full Face Regarding the Treatment of Wrinkles and Skin Quality Characteristics

Mon, 25 Aug 2008 12:38:00 GMT

Isolagen, Inc. announced today results from a prospective, open label, Phase II study of Isolagen Therapy for the treatment of facial wrinkles and creases in approximately 40 subjects. Study subjects received two treatments of Isolagen Therapy in multiple facial regions approximately five weeks apart. The study results reported improvement in the appearance of wrinkles as scored by a high percentage both of study subjects as well as of independent panel evaluators. The study results also reported improvement in skin quality as scored by a high percentage of both study subjects and participating investigators.[More...]

Isolagen, Inc. Receives American Stock Exchange Notice Accepting Its Previously Submitted Plan of Compliance and Canceling the Delisting Hearing

Thu, 14 Aug 2008 20:03:00 GMT

Isolagen, Inc. today announced that on August 14, 2008 it received notice from the American Stock Exchange advising the Company that its previously submitted plan of compliance demonstrates a reasonable course of action by the Company to regain compliance with AMEX's continued listing standards, and that the delisting hearing previously scheduled for August 19, 2008 has been canceled.[More...]